Harold Bernstein Sells 45,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 45,000 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $1,825,200.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Maze Therapeutics Price Performance

Maze Therapeutics stock traded up $1.38 during trading hours on Wednesday, hitting $41.43. The stock had a trading volume of 394,842 shares, compared to its average volume of 325,768. The stock has a market capitalization of $1.99 billion and a price-to-earnings ratio of -1.98. Maze Therapeutics, Inc. has a 1-year low of $6.71 and a 1-year high of $43.29. The stock’s fifty day moving average is $36.34 and its two-hundred day moving average is $24.46.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Institutional Trading of Maze Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. acquired a new position in shares of Maze Therapeutics during the first quarter worth about $796,000. Deutsche Bank AG purchased a new stake in shares of Maze Therapeutics in the first quarter valued at about $98,000. Invesco Ltd. acquired a new stake in Maze Therapeutics during the first quarter worth approximately $226,000. Nuveen LLC purchased a new position in shares of Maze Therapeutics during the 1st quarter worth $125,000. Finally, Corebridge Financial Inc. acquired a new stake in shares of Maze Therapeutics during the first quarter worth $48,000.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research report on Monday, September 29th. Guggenheim reiterated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Friday, December 19th. Wells Fargo & Company initiated coverage on Maze Therapeutics in a research note on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price objective on the stock. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Finally, Raymond James Financial initiated coverage on Maze Therapeutics in a report on Thursday, November 13th. They set an “outperform” rating and a $48.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $43.38.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.